We are excited to share that Jennifer Che, President and Managing Director of Eagle IP, will be attending the Life Sciences Patents Network (LSPN) North America Spring conference, held from April 29–30, 2026, at the Hyatt Regency Boston.

As a premier gathering for the global biopharma and medtech communities, LSPN Boston provides a vital platform for IP leaders to discuss the strategies and legal frameworks driving innovation in the life sciences. With her extensive background as  a medicinal chemist, US Patent Attorney, and Managing Director of a team of Chinese patent attorneys, Jennifer is uniquely positioned to engage with industry peers on the complex IP challenges, especially with respect to Asia, facing modern biotech companies.

If you are attending LSPN Boston and would like to discuss global IP strategy or specific developments in the Asian markets, Jennifer would welcome the opportunity to connect. Please contact us to schedule a meeting during the conference.

我們過去活動

BioHK2026 | Biotech IP in practice

2026年9月16日

Jennifer Che Once Again Named to the IAM Strategy 300

2026年8月21日

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

2026年7月22日

Pauli Wong as a Guest speaker for “Entrepreneurial Workshop” in Poly U

2026年6月16日

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2026 Patent Firms Ranking List

2026年6月5日

Eagle IP Achieves Top Ranking in 2026 IAM Patent 1000

2026年6月2日

Recommended Insights

Updates on Hong Kong Patents Examination Guidelines in 2024

2024年2月29日
The Intellectual Property Department of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China (HKIPD) has recently made several updates to the Hong Kong Patents Examination Guidelines, effective from 26 January, 2024. These changes mainly clarify and reflect the Registry’s current practices regarding patent examination for Standard Patent (R) […]
閱讀更多 >

New Policies to Promote Importation of Innovative Drugs

2018年11月8日
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]
閱讀更多 >

New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference

2024年3月21日
Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
閱讀更多 >

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

2025年2月4日
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
閱讀更多 >
Top crossarrow-right